Just this year, over 50 U.S. genetics and
gene therapy startups raised at least $ 1 million to support genetics - based treatments, including speeding trails, improving accuracy of tests, and providing better platforms.
Not exact matches
Collectively, this new kind of
startup can help drive down the cost of
gene therapy discovery for patients.
And on Wednesday, in a major milestone for this burgeoning and potentially world - changing industry, the Dutch
startup UniQure, developer of the Western world's first approved
gene therapy, raised $ 82 million in its initial public offering, Reuters reports.
While it takes time for
gene therapies to be tested, trialed, and possibly approved by the FDA, genetics
startups like Spark, AveXis, Caribou Biosciences, Editas, and Audentes have been on the road a while.
Editas, a
startup based in Cambridge and founded in November 2013, wants to eventually use the technology to treat disease by coming up with
therapies that can modify faulty disease - causing
genes.
In what could be the start of a new era of do - it - yourself
gene therapy, the CEO of a biotech
startup last month skipped town to undergo a very public round of anti-aging
therapy in Latin America, reports MIT Technology Review.
Oisín Biotechnology — a
startup with initial funding from SENS Research Foundation, the Methuselah Foundation, and others — is close behind them, having developed a form of
gene therapy that — in animals at least — also destroys these cells, using an approach that is less inherently likely to destroy healthy cells along with senescent ones.
A handful of biotechnology
startups are vying to bring CRISPR - based
therapies to market, hoping to cure cystic fibrosis and certain forms of blindness, among other conditions, by getting rid of the bad
genes that cause them.